Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T89534 | ||||
Target Name | Estrogen receptor (ESR) | ||||
Type of Target |
Successful |
||||
Drug Potency against Target | Clomifene | Drug Info | EC50 = 179 nM | [46] | |
Conjugated Estrogens | Drug Info | EC50 = 1.1 nM | [44] | ||
Danazol | Drug Info | IC50 = 57400 nM | |||
Dienestrol | Drug Info | EC50 = 1.1 nM | [44] | ||
Diethylstilbestrol | Drug Info | Ki = 870 nM | [45] | ||
Estradiol | Drug Info | Ec50 = 40 nM | [47] | ||
Estriol | Drug Info | EC50 = 12 nM | [44] | ||
Fulvestrant | Drug Info | IC50 = 9.35 nM | |||
Lasofoxifene | Drug Info | IC50 = 1.2 nM | [42] | ||
Mestranol | Drug Info | EC50 = 9.1 nM | [44] | ||
Mitotane | Drug Info | IC50 = 318000 nM | [43] | ||
Tamoxifen | Drug Info | IC50 = 174 nM | [41] | ||
Toremifene | Drug Info | IC50 = 1000 nM | [29] | ||
Drug Info | IC50 = 2800 nM | [14] | |||
1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol | Drug Info | Ki = 8.5 nM | [19] | ||
1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 43 nM | [17] | ||
1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 266 nM | [17] | ||
1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL | Drug Info | IC50 = 91 nM | [17] | ||
1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 77 nM | [17] | ||
2,3-diphenyl-1H-indole | Drug Info | IC50 = 6950 nM | [20] | ||
2,4-Dibenzylamino-6-isopentylpyrimidine | Drug Info | IC50 = 8300 nM | [31] | ||
2,4-diisobutylamino-6-isopentylpyrimidine | Drug Info | IC50 = 3100 nM | [31] | ||
2-(2-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 139 nM | [13] | ||
2-(3-Butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol | Drug Info | IC50 = 3240 nM | [13] | ||
2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 5280 nM | [13] | ||
2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-6-ol | Drug Info | IC50 = 5000 nM | [13] | ||
2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 1570 nM | [13] | ||
2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol | Drug Info | IC50 = 8430 nM | [13] | ||
2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol | Drug Info | IC50 = 34 nM | [6] | ||
2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-6-ol | Drug Info | IC50 = 16 nM | [6] | ||
2-(4-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol | Drug Info | IC50 = 1900 nM | [13] | ||
2-(4-Hydroxy-phenyl)-4-methoxy-quinolin-6-ol | Drug Info | IC50 = 6630 nM | [18] | ||
2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol | Drug Info | IC50 = 504 nM | [18] | ||
2-(4-Hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol | Drug Info | IC50 = 1200 nM | [13] | ||
2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol | Drug Info | IC50 = 483 nM | [12] | ||
2-(4-Hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol | Drug Info | IC50 = 2557 nM | [13] | ||
2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol | Drug Info | IC50 = 114 nM | [12] | ||
2-(4-Hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol | Drug Info | IC50 = 1300 nM | [13] | ||
2-(4-Hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol | Drug Info | IC50 = 775 nM | [13] | ||
2-(4-Hydroxy-phenyl)-7-propyl-benzooxazol-5-ol | Drug Info | IC50 = 390 nM | [13] | ||
2-(4-Hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol | Drug Info | IC50 = 447 nM | [13] | ||
2-(4-Hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 1227 nM | [13] | ||
2-(4-Hydroxy-phenyl)-benzooxazol-6-ol | Drug Info | IC50 = 902 nM | [13] | ||
2-(4-Hydroxy-phenyl)-quinolin-6-ol | Drug Info | IC50 = 1775 nM | [18] | ||
2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL | Drug Info | IC50 = 176 nM | [13] | ||
2-(4-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol | Drug Info | IC50 = 4.3 nM | [6] | ||
2-(5-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol | Drug Info | IC50 = 117 nM | [13] | ||
2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol | Drug Info | IC50 = 153 nM | [13] | ||
2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol | Drug Info | IC50 = 35 nM | [13] | ||
2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-5-ol | Drug Info | IC50 = 3800 nM | [13] | ||
2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-6-ol | Drug Info | IC50 = 780 nM | [13] | ||
2-Naphthalen-1-yl-benzooxazol-6-ol | Drug Info | IC50 = 1880 nM | [13] | ||
2-phenyl-1,2'-spirobi[1H-indene]-5'-ol | Drug Info | IC50 = 114 nM | [6] | ||
3'-Methoxy-4'Hydroxyclomiphene | Drug Info | IC50 = 780 nM | [38] | ||
3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one | Drug Info | IC50 = 654 nM | [23] | ||
3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one | Drug Info | IC50 = 1170 nM | [23] | ||
3-(2-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol | Drug Info | IC50 = 3000 nM | [13] | ||
3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-5-ol | Drug Info | IC50 = 819 nM | [13] | ||
3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol | Drug Info | IC50 = 815 nM | [13] | ||
3-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol | Drug Info | IC50 = 5110 nM | [13] | ||
3-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol | Drug Info | IC50 = 2353 nM | [13] | ||
3-chloro-4-(4-hydroxyphenyl)salicylaldoxime | Drug Info | Ki = 310 nM | [30] | ||
3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one | Drug Info | IC50 = 585 nM | [23] | ||
4',5,7-trihydroxy-6,8-dimethylisoflavone | Drug Info | IC50 = 10200 nM | [5] | ||
4,10-dimethyl-6H-benzo[c]chromene-3,8-diol | Drug Info | IC50 = 1030 nM | [23] | ||
4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol | Drug Info | IC50 = 1210 nM | [23] | ||
4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol | Drug Info | IC50 = 468 nM | [23] | ||
4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol | Drug Info | IC50 = 237 nM | [23] | ||
4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol | Drug Info | IC50 = 335 nM | [23] | ||
4,7-dimethyl-6H-benzo[c]chromene-3,8-diol | Drug Info | IC50 = 4610 nM | [23] | ||
4-(1,2-Diphenyl-but-1-enyl)-phenol | Drug Info | IC50 = 7 nM | [4] | ||
4-(1-benzyl-7-chloro-1H-indazol-3-yl)phenol | Drug Info | IC50 = 105 nM | [15] | ||
4-(1-butyl-7-chloro-1H-indazol-3-yl)phenol | Drug Info | IC50 = 25 nM | [15] | ||
4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol | Drug Info | IC50 = 18 nM | [15] | ||
4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol | Drug Info | IC50 = 1800 nM | [20] | ||
4-(2-phenyl-1H-indol-3-yl)phenol | Drug Info | IC50 = 24 nM | [20] | ||
4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol | Drug Info | IC50 = 94.8 nM | [20] | ||
4-(3-phenyl-1H-indol-2-yl)phenol | Drug Info | IC50 = 8310 nM | [20] | ||
4-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol | Drug Info | IC50 = 190 nM | [13] | ||
4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol | Drug Info | IC50 = 2410 nM | [13] | ||
4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol | Drug Info | IC50 = 82 nM | [13] | ||
4-(7-chloro-1-cyclohexyl-1H-indazol-3-yl)phenol | Drug Info | IC50 = 37 nM | [15] | ||
4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)phenol | Drug Info | IC50 = 18 nM | [15] | ||
4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol | Drug Info | IC50 = 52 nM | [15] | ||
4-(7-methyl-1-propyl-1H-indazol-3-yl)phenol | Drug Info | IC50 = 40 nM | [15] | ||
4-Benzo[d]isoxazol-3-yl-benzene-1,3-diol | Drug Info | IC50 = 6100 nM | [13] | ||
4-benzyl-2,6-diisobutylamino-pyrimidine | Drug Info | IC50 = 9500 nM | [31] | ||
4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol | Drug Info | IC50 = 212 nM | [18] | ||
4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol | Drug Info | IC50 = 213 nM | [18] | ||
4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol | Drug Info | IC50 = 634 nM | [18] | ||
4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol | Drug Info | IC50 = 1500 nM | [18] | ||
4-hydroxy-N,N-diphenylbenzenesulfonamide | Drug Info | IC50 = 410 nM | [21] | ||
4-hydroxy-N-isopropyl-N-phenylbenzenesulfonamide | Drug Info | IC50 = 871 nM | [21] | ||
4-hydroxy-N-neopentyl-N-phenylbenzenesulfonamide | Drug Info | IC50 = 1371 nM | [21] | ||
4-hydroxy-N-phenyl-N-propylbenzenesulfonamide | Drug Info | IC50 = 303 nM | [21] | ||
4-Naphthalen-2-yl-phenol | Drug Info | IC50 = 638 nM | [17] | ||
4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol | Drug Info | IC50 = 10 nM | [7] | ||
4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol | Drug Info | IC50 = 240 nM | [7] | ||
4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol | Drug Info | IC50 = 70 nM | [7] | ||
4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol | Drug Info | IC50 = 200 nM | [7] | ||
4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol | Drug Info | IC50 = 15 nM | [4] | ||
4-[1-(4-hydroxyphenyl)-2-phenylhex-1-enyl]phenol | Drug Info | IC50 = 500 nM | [4] | ||
4-[1-(4-hydroxyphenyl)-2-phenylpent-1-enyl]phenol | Drug Info | IC50 = 50 nM | [4] | ||
4-[1-(4-hydroxyphenyl)-2-phenylprop-1-enyl]phenol | Drug Info | IC50 = 30 nM | [4] | ||
4-[1-(4-hydroxyphenyl)-2-phenylvinyl]phenol | Drug Info | IC50 = 150 nM | [4] | ||
4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol | Drug Info | IC50 = 15 nM | [7] | ||
5-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol | Drug Info | IC50 = 1140 nM | [18] | ||
5-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol | Drug Info | IC50 = 2765 nM | [13] | ||
5-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol | Drug Info | IC50 = 632 nM | [18] | ||
5-hydroxy-2-phenylisoindoline-1,3-dione | Drug Info | IC50 = 2700 nM | [24] | ||
6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 27 nM | [17] | ||
6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 10.3 nM | [17] | ||
6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 10 nM | [17] | ||
6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 24 nM | [17] | ||
6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 92 nM | [17] | ||
6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 107 nM | [17] | ||
6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 92 nM | [17] | ||
6-(3-Hydroxy-phenyl)-naphthalen-1-ol | Drug Info | IC50 = 1452 nM | [17] | ||
6-(3-Hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 230 nM | [17] | ||
6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 174 nM | [17] | ||
6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 40 nM | [17] | ||
6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol | Drug Info | IC50 = 884 nM | [17] | ||
6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol | Drug Info | IC50 = 282 nM | [17] | ||
6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol | Drug Info | IC50 = 709 nM | [17] | ||
6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol | Drug Info | IC50 = 1231 nM | [17] | ||
6-(4-Hydroxy-phenyl)-naphthalen-1-ol | Drug Info | IC50 = 22 nM | [17] | ||
6-(4-Hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 211 nM | [18] | ||
6-butyl-2,4-dipropylaminopyrimidine | Drug Info | IC50 = 13000 nM | [31] | ||
6-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 464 nM | [13] | ||
6-ethyl-2,4-diisobutylaminopyrimidine | Drug Info | IC50 = 7300 nM | [31] | ||
6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol | Drug Info | IC50 = 101 nM | [23] | ||
6-Phenyl-naphthalen-2-ol | Drug Info | IC50 = 1345 nM | [17] | ||
7-(3-Hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 2642 nM | [17] | ||
7-(4-Hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 442 nM | [17] | ||
7-Allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 727 nM | [13] | ||
7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol | Drug Info | IC50 = 1.5 nM | [12] | ||
7-Butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 498 nM | [13] | ||
7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol | Drug Info | IC50 = 6.8 nM | [12] | ||
7-Ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 537 nM | [13] | ||
7-Ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 481 nM | [13] | ||
7-Phenyl-naphthalen-2-ol | Drug Info | IC50 = 3405 nM | [17] | ||
8-(2,2-dimethylpropyl)naringenin | Drug Info | IC50 = 216 nM | [25] | ||
8-(2-methylpropyl)naringenin | Drug Info | IC50 = 80 nM | [25] | ||
8-(3-methylbutyl)naringenin | Drug Info | IC50 = 140 nM | [25] | ||
8-benzylnaringenin | Drug Info | IC50 = 503 nM | [25] | ||
8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 30 nM | [17] | ||
8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 22 nM | [17] | ||
8-methylnaringenin | Drug Info | IC50 = 5245 nM | [25] | ||
8-n-heptylnaringenin | Drug Info | IC50 = 392 nM | [25] | ||
8-n-nonylnaringenin | Drug Info | IC50 = 436 nM | [25] | ||
8-n-pentylnaringenin | Drug Info | IC50 = 383 nM | [25] | ||
8-n-propylnaringenin | Drug Info | IC50 = 155 nM | [25] | ||
8-n-undecylnaringenin | Drug Info | IC50 = 1017 nM | [25] | ||
Afimoxifene | Drug Info | IC50 = 40 nM | [32] | ||
ARZOXIFENE | Drug Info | IC50 = 21.5 nM | [26] | ||
BITHIONOL | Drug Info | IC50 = 3940.88 nM | [37] | ||
BROUSSONIN A | Drug Info | IC50 = 8100 nM | [35] | ||
Carboron Cluster with phenol | Drug Info | IC50 = 0.59 nM | [9] | ||
COUMESTROL | Drug Info | IC50 = 75.7 nM | [16] | ||
daidzein | Drug Info | IC50 = 17000 nM | [5] | ||
DIHYDRORALOXIFENE | Drug Info | IC50 = 0.52 nM | [1] | ||
Doxorubicin-Formaldehyde Conjugate | Drug Info | IC50 = 300 nM | [10] | ||
EFFUSOL | Drug Info | IC50 = 240 nM | [23] | ||
ERA-923 | Drug Info | IC50 = 1.5 nM | [3] | ||
Geldanamycin-estradiol hybrid | Drug Info | IC50 = 80 nM | [2] | ||
GSK-5182 | Drug Info | IC50 = 320 nM | [22] | ||
HE2100 | Drug Info | IC50 = 180 nM | [28] | ||
HEXESTROL | Drug Info | IC50 = 2 nM | |||
JNJ-17148066 | Drug Info | IC50 = 11 nM | [34] | ||
JNJ-19398990 | Drug Info | IC50 = 1736 nM | [34] | ||
JNJ-26529126 | Drug Info | IC50 = 1210 nM | [34] | ||
JNJ-26529152 | Drug Info | IC50 = 10 nM | [34] | ||
LTERHKILHRLLQEGSPSD | Drug Info | Ki = 190 nM | [27] | ||
MPrP | Drug Info | IC50 = 20 nM | [33] | ||
N,N,N-Triisobutyl-pyrimidine-2,4,6-triamine | Drug Info | IC50 = 2400 nM | [31] | ||
N-allyl-4-hydroxy-N-phenylbenzenesulfonamide | Drug Info | IC50 = 235 nM | [21] | ||
N-benzyl-4-hydroxy-N-phenylbenzenesulfonamide | Drug Info | IC50 = 500 nM | [21] | ||
N-butyl-4-hydroxy-N-phenylbenzenesulfonamide | Drug Info | IC50 = 317 nM | [21] | ||
N-cyclohexyl-4-hydroxy-N-phenylbenzenesulfonamide | Drug Info | IC50 = 866 nM | [21] | ||
N-ethyl-4-hydroxy-N-phenylbenzenesulfonamide | Drug Info | IC50 = 404 nM | [21] | ||
Nafoxidine | Drug Info | IC50 = 40.9 nM | [40] | ||
ONAPRISTONE | Drug Info | Ki < 20 nM | [39] | ||
SOPHORAFLAVANONE B | Drug Info | IC50 = 57 nM | [25] | ||
Tamoxifen butyl bromide | Drug Info | Ki = 13.01 nM | [36] | ||
Tamoxifen ethyl bromide | Drug Info | Ki = 13.66 nM | [36] | ||
Tamoxifen isopropyl bromide | Drug Info | Ki = 25.43 nM | [36] | ||
Tamoxifen methyl iodide | Drug Info | Ki = 46.29 nM | [36] | ||
WAY-169916 | Drug Info | IC50 = 1300 nM | [15] | ||
WAY200070 | Drug Info | IC50 = 155 nM | [13] | ||
ZK-164015 | Drug Info | IC50 = 1.4 nM | [11] | ||
[1,1':2',1'']Terphenyl-4'-carbaldehyde oxime | Drug Info | Ki = 0.15 nM | [8] | ||
Action against Disease Model | Fulvestrant | Drug Info | IC50 in immortalized rat embryonic hypothalamic cell line D12 subclone cells: 0.63 nM | [41] | |
Tamoxifen | Drug Info | IC50 in immortalized rat embryonic hypothalamic cell line D12 subclone cells: 174 nM | [41] | ||
References | |||||
REF 1 | Synthesis and biological activity of trans-2,3-dihydroraloxifene. Bioorg Med Chem Lett. 1999 Apr 19;9(8):1137-40. | ||||
REF 2 | Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8. | ||||
REF 3 | Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem. 2001 May 24;44(11):1654-7. | ||||
REF 4 | Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphen... J Med Chem. 2002 Nov 21;45(24):5358-64. | ||||
REF 5 | Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis. J Nat Prod. 2002 Dec;65(12):1749-53. | ||||
REF 6 | 2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83. | ||||
REF 7 | Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91. | ||||
REF 8 | Novel estrogen receptor ligands based on an anthranylaldoxime structure: role of the phenol-type pseudocycle in the binding process. J Med Chem. 2003 Sep 11;46(19):4032-42. | ||||
REF 9 | Utility of boron clusters for drug design. Relation between estrogen receptor binding affinity and hydrophobicity of phenols bearing various types ... Bioorg Med Chem Lett. 2003 Nov 17;13(22):4089-92. | ||||
REF 10 | Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells. J Med Chem. 2004 Feb 26;47(5):1193-206. | ||||
REF 11 | Synthesis and biological evaluation of stilbene-based pure estrogen antagonists. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4659-63. | ||||
REF 12 | 7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9. | ||||
REF 13 | Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. | ||||
REF 14 | Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancers-molecular modeling studies. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5919-24. | ||||
REF 15 | Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8. | ||||
REF 16 | Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative ... J Med Chem. 2005 May 19;48(10):3463-6. | ||||
REF 17 | ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. | ||||
REF 18 | ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. | ||||
REF 19 | Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands. J Med Chem. 2005 Sep 22;48(19):5989-6003. | ||||
REF 20 | Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. | ||||
REF 21 | Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. | ||||
REF 22 | Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma. Bioorg Med Chem Lett. 2006 Feb 15;16(4):821-4. | ||||
REF 23 | 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. | ||||
REF 24 | Estrogen receptor beta ligands: design and synthesis of new 2-phenyl-isoindole-1,3-diones. Bioorg Med Chem Lett. 2007 Jan 1;17(1):118-22. | ||||
REF 25 | Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. | ||||
REF 26 | Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92. | ||||
REF 27 | Bicyclo[2.2.2]octanes: close structural mimics of the nuclear receptor-binding motif of steroid receptor coactivators. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4118-22. | ||||
REF 28 | Androstene-3,5-dienes as ER-beta selective SERMs. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6295-8. | ||||
REF 29 | Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):1-7. | ||||
REF 30 | Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor beta. J Med Chem. 2008 Mar 13;51(5):1344-51. | ||||
REF 31 | Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem. 2008 Oct 23;51(20):6512-30. | ||||
REF 32 | Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators. Bioorg Med Chem. 2008 Nov 1;16(21):9554-73. | ||||
REF 33 | Analogs of methyl-piperidinopyrazole (MPP): antiestrogens with estrogen receptor alpha selective activity. Bioorg Med Chem Lett. 2009 Jan 1;19(1):108-10. | ||||
REF 34 | Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symp... J Med Chem. 2009 Dec 10;52(23):7544-69. | ||||
REF 35 | New estrogenic compounds isolated from Broussonetia kazinoki. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3764-7. | ||||
REF 36 | Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha. Bioorg Med Chem. 2010 Aug 1;18(15):5593-601. | ||||
REF 37 | In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. | ||||
REF 38 | Phenolic metabolites of clomiphene: [(E,Z)-2-[4-(1,2-diphenyl-2-chlorovinyl)phenoxy]ethyl]diethylamine. Preparation, electrophilicity, and effects ... J Med Chem. 1989 Jan;32(1):192-7. | ||||
REF 39 | Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether. J Med Chem. 1996 Apr 26;39(9):1778-89. | ||||
REF 40 | Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthal... J Med Chem. 1998 Jul 30;41(16):2928-31. | ||||
REF 41 | Effect of estrogen agonists and antagonists on induction of progesterone receptor in a rat hypothalamic cell line. Endocrinology. 1999 Sep;140(9):3928-37. | ||||
REF 42 | Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology. 2000 Apr;141(4):1338-44. | ||||
REF 43 | Recombinant human estrogen, androgen and progesterone receptors for detection of potential endocrine disruptors. Anal Bioanal Chem. 2004 Feb;378(3):664-9. | ||||
REF 44 | Rapid yeast estrogen bioassays stably expressing human estrogen receptors alpha and beta, and green fluorescent protein: a comparison of different compounds with both receptor types. J Steroid Biochem Mol Biol. 2004 Jul;91(3):99-109. | ||||
REF 45 | Estrogen-related receptors as emerging targets in cancer and metabolic disorders. Curr Top Med Chem. 2006;6(3):203-15. | ||||
REF 46 | Interaction of stilbene compounds with human and rainbow trout estrogen receptors. Environ Toxicol Chem. 2008 Feb;27(2):442-51. | ||||
REF 47 | Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. Mol Endocrinol. 1997 Nov;11(12):1868-78. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.